Skip to main content
U.S. flag

An official website of the United States government

Osthole upregulates BDNF to enhance adult hippocampal neurogenesis in APP/PS1 transgenic mice

Bibliographic

Year of Publication:
2015
Contact PI Name:
Xue Xinhong
Contact PI Affiliation:
Department of Neurology, Liaocheng Hospital, Liaocheng, China
Co-Authors:
Hong Liu, Huijian Shi, Lifeng Qi, Dianrong Gong
Primary Reference (PubMED ID):
Funding Source:
Not Reported
Study Goal and Principal Findings:

Adult hippocampal neurogenesis occurs in the dentate gyrus (DG) of the mouse hippocampus, and plays roles in learning and memory progresses. In amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice, a rodent model of Alzheimer's disease (AD), severe impairment of neurogenesis in the dentate subgranular zone (SGZ) of the DG has been reported. Osthole, an active constituent of Cnidium monnieri (L.) CUSSON, has been reported to exert neuroprotective effects and may promote neural stem cell proliferation. However, whether osthole ameliorates spatial memory deficits and improves hippocampal neurogenesis in APP/PS1 mice remains unknown. In this study was found that osthole (30 mg/kg intraperitoneally (i.p.) once daily) treatment dramatically ameliorated the cognitive impairments by Morris Water Maze test and passive avoidance test, and augmented neurogenesis in the DG of hippocampus in APP/PS1 mice. Furthermore, osthole treatment upregulated expression of brain-derived neurotrophic factor (BDNF) and enhanced activation of the BDNF receptor tyrosine receptor kinase B (TrkB) following increased phosphorylation of cyclic AMP response element-binding protein (CREB), indicating that osthole improves neurogenesis via stimulating BDNF/TrkB/CREB signaling in APP/PS1 transgenic mice.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Osthole
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
Non-transgenic
Strain/Genetic Background:
C57BL/6J
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Passive Avoidance Test
Histopathology
beta Amyloid Deposits
beta Amyloid Load
Biochemical
Brain-Derived Neurotrophic Factor (BDNF)
phospho-cAMP Response Element-Binding Protein (phospho-CREB)
phospho-Tyrosine Receptor Kinase B (phospho-TrKB)
Tyrosine Receptor Kinase B (TrkB)
cAMP Response Element-Binding Protein (CREB)
Immunochemistry
Neurogenesis
Brain-beta Amyloid Deposits
Brain-beta Amyloid Peptide 40
Neural Stem Cells
Cell Proliferation
Neuronal Marker NeuN
Nestin